Charles River Laboratories International (CRL) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Charles River Laboratories International (CRL) over the past year, gaining 163.2% versus a gain of 71.8%. Over five years, CRL leads with a -26.2% price change compared with -52.0% for OABI. Charles River Laboratories International is the larger company by market cap ($14.54 billion vs $696.4 million), about 20.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | OABI |
|---|---|---|
| Share price | $301.79 | $4.79 |
| Market cap | $14.54B | $696.42M |
| 1-day change | +1.27% | +2.79% |
| YTD return | +49.39% | +158.92% |
| 1-year return | +71.79% | +163.19% |
| 5-year return | -26.15% | -51.96% |
| Forward P/E | 23.62 | — |
| EPS (TTM) | $-4.86 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.02B | — |
| Revenue growth (YoY) | -0.85% | — |
| Net income (latest FY) | $-144.34M | — |
| Operating margin | 0.63% | — |
| Net margin | -3.59% | — |
| 52-week high | $333.30 | $5.43 |
| 52-week low | $146.20 | $1.30 |
| Distance from 52-week high | -9.45% | -11.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1.06% | +73.90% |
| Average volume | 957.45K | 1.47M |
| Shares outstanding | 48.17M | 145.39M |
| Employees | 18,300 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Charles River Laboratories International is about 20.9 times larger than OmniAb by market value ($14.54B vs $696.42M).
- OABI has outperformed CRL by 91.4 percentage points over the past year.
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
CRL vs OABI FAQ
Which is bigger, Charles River Laboratories International or OmniAb?
Charles River Laboratories International (CRL) is larger, with a market capitalization of $14.54B compared with $696.42M for OmniAb (OABI).
Which stock has performed better over the past year, CRL or OABI?
OABI returned +163.19% over the past 12 months, compared with +71.79% for CRL (price return, excluding dividends). Past performance does not predict future results.
Are Charles River Laboratories International and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.